FDA issues alert on potential dangers of unproven treatment for multiple sclerosis
The U.S. Food and Drug Administration is alerting health care professionals and patients about injuries and death associated with the use of an experimental procedure sometimes called liberation therapy or the liberation procedure to treat chronic cerebrospinal venous insufficiency (CCSVI).